Discovery of 4-(phenyl)thio-1H-pyrazole derivatives as agonists of GPR109A, a high affinity niacin receptor

Differential tissue and ligand-dependent signaling of GPR109A receptor: Implications for anti-atherosclerotic therapeutic potential

(2013) Ibragim Gaidarov et al.   CELLULAR SIGNALLING

(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic Acid (MK-1903): A Potent GPR109a Agonist that Lowers Free Fatty Acids in Humans

(2012) P. Douglas Boatman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia

(2011) Anandan Palani et al.   ACS Medicinal Chemistry Letters

Internalization of the Human Nicotinic Acid Receptor GPR109A Is Regulated by Gi, GRK2, and Arrestin3

(2010) Guo Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Nicotinic acid– and monomethyl fumarate–induced flushing involves GPR109A expressed by keratinocytes and COX-2–dependent prostanoid formation in mice

(2010) Julien Hanson et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate

(2010) Hong C. Shen et al.   JOURNAL OF MEDICINAL CHEMISTRY

β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice

(2009) Robert W. Walters et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular modeling aided design of nicotinic acid receptor GPR109A agonists

(2008) Qiaolin Deng et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans

(2008) Eseng Lai et al.   Journal of Clinical Lipidology

Synthesis of functionalized diaryl sulfides based on regioselective one-pot cyclizations of 1,3-bis(trimethylsilyloxy)-1,3-butadienes

(2008) Muhammad A. Rashid et al.   TETRAHEDRON